Compare EVGO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVGO | TNGX |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.6M | 4.1B |
| IPO Year | 2020 | 2020 |
| Metric | EVGO | TNGX |
|---|---|---|
| Price | $1.39 | $23.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $5.23 | ★ $21.78 |
| AVG Volume (30 Days) | ★ 3.3M | 2.1M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.39 | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | $54,588,000.00 | ★ $62,384,000.00 |
| Revenue This Year | $16.45 | N/A |
| Revenue Next Year | $29.44 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 145.74 | 48.29 |
| 52 Week Low | $1.37 | $6.25 |
| 52 Week High | $5.18 | $34.39 |
| Indicator | EVGO | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 39.97 | 39.87 |
| Support Level | $1.42 | $19.74 |
| Resistance Level | $1.69 | $25.76 |
| Average True Range (ATR) | 0.07 | 1.37 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 13.79 | 26.73 |
EVgo Inc is an EV fast charging provider. The company deploys charging infrastructure by partnering with retailers, grocery stores, restaurants, gas stations, rideshare operators, and autonomous vehicle companies across the U.S., and serves the EV commercial segment by deploying fleet-charging solutions for light-duty EV fleets at depot locations, off-site charging hubs, or through its public network. It also owns PlugShare, a platform for EV drivers to locate public charging stations, plan trips and share charging experiences, which also provides charging location data licensing, infrastructure analysis, and EV driver research. It also derives revenue from the sale of regulatory credits earned from participation in LCFS programs and other carbon or emissions trading schemes in the U.S.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.